英文名稱(chēng) | Mifamurtide | CGP-19835| MTP-PE | L-MTP-PE |
---|---|
中文名稱(chēng) | 米法莫肽 | 米伐木肽 |
CAS號(hào) | 83461-56-7 |
分子式 | C59H109N6O19P |
分子量 | 1,237.50 |
外觀 | White to off-white powder |
儲(chǔ)存條件 | -20°C, stored under nitrogen |
規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專(zhuān)享價(jià) | 數(shù)量 |
---|---|---|---|---|
1 mg | In-stock | ¥2866.00 | 登錄后可見(jiàn) | |
5 mg | In-stock | ¥9866.00 | 登錄后可見(jiàn) |
英文名稱(chēng) | Mifamurtide | CGP-19835| MTP-PE | L-MTP-PE |
---|---|
中文名稱(chēng) | 米法莫肽 | 米伐木肽 |
CAS號(hào) | 83461-56-7 |
分子式 | C59H109N6O19P |
分子量 | 1,237.50 |
外觀 | White to off-white powder |
儲(chǔ)存條件 | -20°C, stored under nitrogen |
Mifamurtide (MTP-PE), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide has potential for use in rare disease and osteosarcoma research.
PMID: 27152244 PMCID: PMC4851846
Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4.
PMID: 28434881 DOI: 10.1016/j.cmet.2017.03.021
PMID: 18298131 DOI: 10.2165/00126839-200809020-00007